 Ian Carroll
Concepts (60)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cerebrospinal Fluid Leak | 1 | 2022 | 28 | 0.830 |
Why?
| | Spine | 1 | 2022 | 135 | 0.750 |
Why?
| | Propanolamines | 2 | 2021 | 90 | 0.340 |
Why?
| | Atrial Fibrillation | 2 | 2021 | 324 | 0.270 |
Why?
| | Receptors, Adrenergic, beta-1 | 2 | 2021 | 45 | 0.230 |
Why?
| | Heart Failure | 3 | 2021 | 1952 | 0.210 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2023 | 80 | 0.210 |
Why?
| | Ventricular Fibrillation | 1 | 2023 | 51 | 0.210 |
Why?
| | Antifibrinolytic Agents | 1 | 2023 | 50 | 0.210 |
Why?
| | ST Elevation Myocardial Infarction | 1 | 2023 | 50 | 0.200 |
Why?
| | Electrocardiography | 2 | 2021 | 562 | 0.190 |
Why?
| | Blood Coagulation Disorders | 1 | 2023 | 192 | 0.180 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2021 | 287 | 0.180 |
Why?
| | Biological Products | 1 | 2023 | 167 | 0.180 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2023 | 346 | 0.180 |
Why?
| | Venous Thromboembolism | 1 | 2023 | 231 | 0.170 |
Why?
| | Phosphodiesterase 3 Inhibitors | 1 | 2019 | 13 | 0.160 |
Why?
| | Data Interpretation, Statistical | 1 | 2018 | 322 | 0.140 |
Why?
| | Feeding and Eating Disorders | 1 | 2017 | 103 | 0.130 |
Why?
| | Models, Statistical | 1 | 2018 | 604 | 0.120 |
Why?
| | Receptors, Adrenergic | 2 | 2023 | 35 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 1 | 2022 | 3039 | 0.100 |
Why?
| | Polymorphism, Genetic | 2 | 2023 | 612 | 0.080 |
Why?
| | Humans | 9 | 2023 | 114756 | 0.060 |
Why?
| | Genotype | 2 | 2021 | 1774 | 0.060 |
Why?
| | Thromboplastin | 1 | 2023 | 71 | 0.050 |
Why?
| | Norepinephrine | 1 | 2023 | 200 | 0.050 |
Why?
| | Heparin | 1 | 2023 | 222 | 0.050 |
Why?
| | Gene Regulatory Networks | 1 | 2023 | 228 | 0.050 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2019 | 10 | 0.040 |
Why?
| | Pharmacogenomic Variants | 1 | 2019 | 33 | 0.040 |
Why?
| | Metoprolol | 1 | 2019 | 37 | 0.040 |
Why?
| | Anticoagulants | 1 | 2023 | 547 | 0.040 |
Why?
| | Hemorrhage | 1 | 2023 | 618 | 0.040 |
Why?
| | Pharmacogenomic Testing | 1 | 2019 | 53 | 0.040 |
Why?
| | Signal Transduction | 2 | 2023 | 4521 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2023 | 1951 | 0.040 |
Why?
| | Cyclic AMP | 1 | 2019 | 225 | 0.040 |
Why?
| | Pharmacogenetics | 1 | 2019 | 149 | 0.040 |
Why?
| | Myocardial Contraction | 1 | 2019 | 312 | 0.040 |
Why?
| | Mortality | 1 | 2019 | 288 | 0.040 |
Why?
| | Stroke Volume | 1 | 2019 | 508 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1080 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2023 | 3005 | 0.030 |
Why?
| | Precision Medicine | 1 | 2019 | 338 | 0.030 |
Why?
| | Male | 4 | 2023 | 55579 | 0.030 |
Why?
| | Myocytes, Cardiac | 1 | 2019 | 448 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 878 | 0.030 |
Why?
| | Female | 4 | 2023 | 59507 | 0.030 |
Why?
| | Inflammation | 1 | 2023 | 2481 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2021 | 4420 | 0.030 |
Why?
| | Aged | 2 | 2021 | 19094 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2386 | 0.020 |
Why?
| | Middle Aged | 2 | 2023 | 26757 | 0.020 |
Why?
| | Time Factors | 1 | 2021 | 6124 | 0.020 |
Why?
| | Mice | 1 | 2023 | 14916 | 0.020 |
Why?
| | Young Adult | 1 | 2017 | 10463 | 0.010 |
Why?
| | Animals | 1 | 2023 | 31761 | 0.010 |
Why?
| | Adolescent | 1 | 2017 | 17808 | 0.010 |
Why?
| | Adult | 1 | 2017 | 30548 | 0.010 |
Why?
|
|
Carroll's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|